Experimental drug targets rare eye cancer in small trial
NCT ID NCT00244816
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a drug called Taxoprexin (DHA-paclitaxel) in 22 people with metastatic uveal melanoma, a rare eye cancer that has spread. The drug was given weekly for 5 weeks in a 6-week cycle. The main goal was to see if tumors shrank or disappeared, and to check safety. The study is complete, but results are not yet widely known.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Taxoprexin (DHA-paclitaxel)
What this could lead to
If it works, this could point toward a treatment option for metastatic uveal melanoma, a rare eye cancer with limited therapies.
What could go wrong
This is a small, early-phase trial with only 22 participants, so results may not apply broadly. The drug may not shrink tumors or improve survival, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030-4009, United States